• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

心率加快与动脉粥样硬化:伊伐布雷定治疗的潜在影响

Increased heart rate and atherosclerosis: potential implications of ivabradine therapy.

作者信息

Dominguez-Rodriguez Alberto, Blanco-Palacios Gabriela, Abreu-Gonzalez Pedro

机构信息

Alberto Dominguez-Rodriguez, Gabriela Blanco-Palacios, Department of Cardiology, Hospital Universitario de Canarias, Tenerife, E-38320, La Laguna, Spain.

出版信息

World J Cardiol. 2011 Apr 26;3(4):101-4. doi: 10.4330/wjc.v3.i4.101.

DOI:10.4330/wjc.v3.i4.101
PMID:21526046
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3082732/
Abstract

Despite all the therapeutic advances in the field of cardiology, cardiovascular diseases, and in particular coronary artery disease, remain the leading cause of death and disability worldwide, thereby underlining the importance of acquiring new therapeutic options in this field. A reduction in elevated resting heart rate (HR) has long been postulated as a therapeutic approach in the management of cardiovascular disease. An increased HR has been shown to be associated with increased progression of coronary atherosclerosis in animal models and patients. A high HR has also been associated with a greatly increased risk of plaque rupture in patients with coronary atherosclerosis. Endothelial function may be an important link between HR and atherosclerosis. An increased HR has been shown experimentally to cause endothelial dysfunction. Inflammation plays a significant role in the pathogenesis and progression of atherosclerosis. In the literature, there is data that shows an association between HR and circulating markers of vascular inflammation. In addition, HR reduction by pharmacological intervention with ivabradine (a selective HR-lowering agent that acts by inhibiting the pacemaker ionic current I(f) in sinoatrial node cells) reduces the formation of atherosclerotic plaques in animal models of lipid-induced atherosclerosis. The aim of this editorial is to review the possible role of ivabradine on atherosclerosis.

摘要

尽管心脏病学领域在治疗方面取得了诸多进展,但心血管疾病,尤其是冠状动脉疾病,仍然是全球范围内导致死亡和残疾的主要原因,这凸显了在该领域获取新治疗方案的重要性。长期以来,降低静息心率(HR)一直被认为是心血管疾病管理中的一种治疗方法。在动物模型和患者中,已证明心率增加与冠状动脉粥样硬化进展加快有关。高心率还与冠状动脉粥样硬化患者斑块破裂风险大幅增加有关。内皮功能可能是心率与动脉粥样硬化之间的重要联系。实验表明,心率增加会导致内皮功能障碍。炎症在动脉粥样硬化的发病机制和进展中起重要作用。文献中有数据表明心率与血管炎症循环标志物之间存在关联。此外,通过使用伊伐布雷定(一种通过抑制窦房结细胞起搏离子电流I(f)起作用的选择性降心率药物)进行药物干预降低心率,可减少脂质诱导的动脉粥样硬化动物模型中动脉粥样硬化斑块的形成。这篇社论的目的是综述伊伐布雷定对动脉粥样硬化可能的作用。

相似文献

1
Increased heart rate and atherosclerosis: potential implications of ivabradine therapy.心率加快与动脉粥样硬化:伊伐布雷定治疗的潜在影响
World J Cardiol. 2011 Apr 26;3(4):101-4. doi: 10.4330/wjc.v3.i4.101.
2
Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease.伊伐布雷定通过特异性和选择性抑制I(f)电流降低心率:心血管疾病治疗的新视角。
Drugs. 2004;64(16):1757-65. doi: 10.2165/00003495-200464160-00003.
3
Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice.伊伐布雷定降低心率可减轻氧化应激、改善内皮功能并预防载脂蛋白E缺乏小鼠的动脉粥样硬化。
Circulation. 2008 May 6;117(18):2377-87. doi: 10.1161/CIRCULATIONAHA.107.746537. Epub 2008 Apr 28.
4
Ivabradine: Evidence and current role in cardiovascular diseases and other emerging indications.伊伐布雷定:心血管疾病及其他新适应症的证据与当前作用
Indian Heart J. 2018 Dec;70 Suppl 3(Suppl 3):S435-S441. doi: 10.1016/j.ihj.2018.08.008. Epub 2018 Aug 20.
5
Heart rate as a treatable cardiovascular risk factor.心率作为一种可治疗的心血管危险因素。
Br Med Bull. 2009;90:71-84. doi: 10.1093/bmb/ldp016. Epub 2009 May 27.
6
Advances in the management of heart failure: the role of ivabradine.心力衰竭管理的进展:伊伐布雷定的作用
Vasc Health Risk Manag. 2016 Nov 17;12:453-470. doi: 10.2147/VHRM.S90383. eCollection 2016.
7
Ivabradine for the Treatment of Cardiovascular Diseases.伊伐布雷定治疗心血管疾病。
Circ J. 2019 Jan 25;83(2):252-260. doi: 10.1253/circj.CJ-18-1184. Epub 2018 Dec 29.
8
The discovery of the selective I(f) current inhibitor ivabradine. A new therapeutic approach to ischemic heart disease.选择性If电流抑制剂伊伐布雷定的发现。缺血性心脏病的一种新治疗方法。
Pharmacol Res. 2006 May;53(5):424-34. doi: 10.1016/j.phrs.2006.03.016. Epub 2006 Mar 28.
9
[The efficacy of ivabradine in chronic heart failure (review)].伊伐布雷定治疗慢性心力衰竭的疗效(综述)
Georgian Med News. 2015 Apr(241):44-9.
10
Ivabradine: the hope for a good treatment of ischemic heart disease.伊伐布雷定:治疗缺血性心脏病的新希望。
Curr Med Chem. 2013;20(14):1817-23. doi: 10.2174/0929867311320140002.

引用本文的文献

1
Resting heart rate as a possible biomarker and target to prevent future cardiovascular disease in type 2 diabetes patients (HTR-2023-0066.R2).静息心率作为2型糖尿病患者预防未来心血管疾病的潜在生物标志物和靶点(HTR - 2023 - 0066.R2)。
Hypertens Res. 2023 May;46(5):1160-1162. doi: 10.1038/s41440-023-01251-9. Epub 2023 Mar 8.
2
Initial in-hospital heart rate is associated with long-term survival in patients with acute ischemic stroke.初始住院心率与急性缺血性脑卒中患者的长期生存相关。
Clin Res Cardiol. 2022 Jun;111(6):651-662. doi: 10.1007/s00392-021-01953-5. Epub 2021 Oct 23.
3
Electroacupuncture Ameliorates Acute Myocardial Ischemia: A Potential Role of the Locus Coeruleus.电针改善急性心肌缺血:蓝斑的潜在作用
Evid Based Complement Alternat Med. 2020 Mar 31;2020:4298657. doi: 10.1155/2020/4298657. eCollection 2020.
4
Real-world heart rate norms in the Health eHeart study.健康电子心脏研究中的真实世界心率规范。
NPJ Digit Med. 2019 Jun 25;2:58. doi: 10.1038/s41746-019-0134-9. eCollection 2019.
5
Channel as an Emerging Therapeutic Target for Cardiovascular Diseases: A Review of Current Evidence and Controversies.通道作为心血管疾病的新兴治疗靶点:当前证据与争议综述
Front Pharmacol. 2017 Nov 24;8:874. doi: 10.3389/fphar.2017.00874. eCollection 2017.
6
Heart rate lowering treatment leads to a reduction in vulnerable plaque features in atherosclerotic rabbits.降低心率治疗可减少动脉粥样硬化兔体内易损斑块特征。
PLoS One. 2017 Jun 22;12(6):e0179024. doi: 10.1371/journal.pone.0179024. eCollection 2017.
7
Ivabradine, coronary artery disease, and heart failure: beyond rhythm control.伊伐布雷定、冠状动脉疾病与心力衰竭:超越节律控制
Drug Des Devel Ther. 2014 Jun 3;8:689-700. doi: 10.2147/DDDT.S60591. eCollection 2014.
8
The biological effects of ivabradine in cardiovascular disease.依伐布雷定在心血管疾病中的生物学效应。
Molecules. 2012 Apr 30;17(5):4924-35. doi: 10.3390/molecules17054924.
9
Prognostic significance of heart rate in hospitalized patients presenting with myocardial infarction.心率对心肌梗死住院患者的预后意义
World J Cardiol. 2012 Jan 26;4(1):15-9. doi: 10.4330/wjc.v4.i1.15.

本文引用的文献

1
Ivabradine: recent and potential applications in clinical practice.伊伐布雷定:临床实践中的最新及潜在应用。
Expert Opin Pharmacother. 2011 Feb;12(3):443-50. doi: 10.1517/14656566.2011.548321.
2
Vascular pathophysiology in response to increased heart rate.心率增加时的血管病理生理学。
J Am Coll Cardiol. 2010 Dec 7;56(24):1973-83. doi: 10.1016/j.jacc.2010.09.014.
3
Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial.心率作为慢性心力衰竭的危险因素(SHIFT):一项随机安慰剂对照试验中心率与结局的关系。
Lancet. 2010 Sep 11;376(9744):886-94. doi: 10.1016/S0140-6736(10)61259-7.
4
Heart rate reduction with ivabradine improves erectile dysfunction in parallel to decrease in atherosclerotic plaque load in ApoE-knockout mice.伊伐布雷定降低心率可改善动脉粥样硬化斑块负荷,从而改善 ApoE 基因敲除小鼠的勃起功能障碍。
Atherosclerosis. 2010 Sep;212(1):55-62. doi: 10.1016/j.atherosclerosis.2010.03.002. Epub 2010 Mar 9.
5
The rationale for comparative studies of accelerated atherosclerosis in rheumatic diseases.风湿性疾病加速动脉粥样硬化比较研究的原理。
Curr Vasc Pharmacol. 2010 Jul;8(4):437-49. doi: 10.2174/157016110791330852.
6
Heart rate as a treatable cardiovascular risk factor.心率作为一种可治疗的心血管危险因素。
Br Med Bull. 2009;90:71-84. doi: 10.1093/bmb/ldp016. Epub 2009 May 27.
7
Randomised, double-blind, placebo-controlled trial of ivabradine in patients with acute coronary syndrome: effects of the If current inhibitor ivabradine on reduction of inflammation markers in patients with acute coronary syndrome--RIVIERA trial study design and rationale.伊伐布雷定治疗急性冠状动脉综合征患者的随机、双盲、安慰剂对照试验:If电流抑制剂伊伐布雷定对降低急性冠状动脉综合征患者炎症标志物的作用——里维埃拉试验研究设计与原理
Cardiovasc Drugs Ther. 2009 Jun;23(3):243-7. doi: 10.1007/s10557-009-6164-9. Epub 2009 Feb 20.
8
Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial.If电流抑制剂伊伐布雷定在接受β受体阻滞剂治疗的慢性稳定型心绞痛患者中的疗效:一项为期4个月的随机安慰剂对照试验。
Eur Heart J. 2009 Mar;30(5):540-8. doi: 10.1093/eurheartj/ehn571. Epub 2009 Jan 9.
9
Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension.β受体阻滞剂引起的心率降低与高血压患者心脏保护作用的关系
J Am Coll Cardiol. 2008 Oct 28;52(18):1482-9. doi: 10.1016/j.jacc.2008.06.048.
10
Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial.心率作为冠心病合并左心室收缩功能不全患者的预后风险因素(BEAUTIFUL研究):一项随机对照试验的亚组分析
Lancet. 2008 Sep 6;372(9641):817-21. doi: 10.1016/S0140-6736(08)61171-X. Epub 2008 Aug 29.